Differentiation therapy, i.e., all-trans retinoic acid (ATRA) and arsenic trioxide, has been shown to be an effective treatment for acute promyelocytic leukemia (APL), a distinct AML subtype characterized by the expression of the PML/RARA fusion protein [23]. Here, RARA is linked to acute myeloid leukemia.